RB
Robert Bruce (Bruce & Co) disclosed reduced in Abbott
Robert Bruce (Bruce & Co) filed a 13F change in Abbott (2824100) on 2026-02-13, covering period end 2025-12-31.
Action
Reduced
Capital
$14,258,002 current disclosed value
Institutional 13F Signals1 evidence source
Why it matters
This signal is selected by portfolio impact within the manager filing, while the full filing change list remains available in the briefing.
Full Filing Changes
39 changes from Robert Bruce (Bruce & Co), filed 2026-02-13 for period end 2025-12-31.
$322.5M portfolio value
| Stock | Action | Change | Current | Portfolio Impact |
|---|---|---|---|---|
925815102 Vicor | Increased | $5.4M | $9.9M | 1.67% |
N00985106 AerCap Holdings | Increased | $4.2M | $26.4M | 1.29% |
589331107 Merck | Increased | $4.1M | $20.3M | 1.28% |
2824100 Abbott | Reduced | -$3.7M | $14.3M | 1.14% |
45774W108 Insteel | Reduced | -$2.3M | $10.9M | 0.71% |
23586506 Uhaul B | Reduced | -$1.9M | $21.1M | 0.58% |
00206R102 AT & T | Reduced | -$1.8M | $13.0M | 0.55% |
651639106 Newmont | Increased | $1.6M | $10.0M | 0.48% |
00287Y109 Abbvie | Reduced | -$1.5M | $28.0M | 0.47% |
98389B100 XCEL Energy | Reduced | -$1.3M | $14.4M | 0.41% |
302571104 Nextera Energy | Increased | $1.1M | $24.9M | 0.35% |
26441C204 Duke Energy | Reduced | -$1.0M | $18.3M | 0.32% |
163851108 Chemours | Reduced | -$1.0M | $2.9M | 0.31% |
20002101 Allstate | Reduced | -$815,750 | $26.1M | 0.25% |
92333F101 Venture Global | Reduced | -$737,000 | $682,000 | 0.23% |
37833100 Apple | Increased | $670,247 | $10.6M | 0.21% |
532457108 Eli Lilly | Increased | $623,360 | $2.1M | 0.19% |
125896100 CMS Energy | Reduced | -$519,480 | $10.9M | 0.16% |
23586100 Uhaul | Reduced | -$492,174 | $3.7M | 0.15% |
268311107 EDAP | Increased | $429,879 | $1.4M | 0.13% |
N53745100 Lyondellbasell | Reduced | -$344,400 | $2.6M | 0.11% |
H11356104 Bunge | Reduced | -$264,340 | $6.2M | 0.08% |
91911K102 Bausch Health | Reduced | -$241,150 | $861,800 | 0.07% |
65443P102 908 Devices | Reduced | -$239,683 | $358,502 | 0.07% |
237266101 Darling Ingredients | Reduced | -$227,970 | $3.8M | 0.07% |
39483102 Archer Daniels | Reduced | -$225,000 | $5.7M | 0.07% |
71535D106 Personalis | Increased | $205,120 | $1.9M | 0.06% |
31189P102 Fate Theraputics | Reduced | -$202,277 | $716,500 | 0.06% |
142038108 Caribou Biosciences | Reduced | -$185,000 | $397,500 | 0.06% |
82968B103 XM Sirius | Reduced | -$182,972 | $1.1M | 0.06% |
44209104 Ashland | Increased | $161,400 | $880,050 | 0.05% |
717081103 Pfizer | Reduced | -$157,702 | $6.8M | 0.05% |
868459108 Supernus | Increased | $156,821 | $4.1M | 0.05% |
92556V106 Viatris | Increased | $148,612 | $725,574 | 0.05% |
05379B107 Avista | Increased | $147,095 | $7.8M | 0.05% |
56400P706 Mannkind | Increased | $58,522 | $1.1M | 0.02% |
749607107 RLI | Reduced | -$50,592 | $2.6M | 0.02% |
50015M109 Kodiak Sciences | Increased | $41,128 | $4.6M | 0.01% |
92939U106 WEC Energy | Reduced | -$36,018 | $416,040 | 0.01% |